ID   LNCaP95 clone E2
AC   CVCL_A4EC
DR   cancercelllines; CVCL_A4EC
DR   Wikidata; Q105509935
RX   PubMed=32954481;
CC   Population: Caucasian.
CC   Characteristics: Androgen-independent.
CC   Doubling time: 64.1 hours (PubMed=32954481).
CC   Sequence variation: Mutation; HGNC; 644; AR; Simple; p.Thr878Ala (c.2632A>G); ClinVar=VCV000009831; Zygosity=Hemizygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 7010; MEN1; Simple; p.Tyr318Ter (c.954T>G) (p.Tyr313Ter, c.939T>A); ClinVar=VCV000439894; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 8979; PIK3R1; Simple; p.Arg639Ter (c.1915C>T); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys6Argfs*4 (c.17_18delAA); ClinVar=VCV000231649; Zygosity=Unspecified (from parent cell line).
CC   Derived from site: Metastatic; Left supraclavicular lymph node; UBERON=UBERON_8480056.
DI   NCIt; C4863; Prostate carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_ZC87 ! LNCaP-95
SX   Male
AG   50Y
CA   Cancer cell line
DT   Created: 12-01-21; Last updated: 05-10-23; Version: 6
//
RX   PubMed=32954481; DOI=10.1007/s13577-020-00435-6; PMCID=PMC8693726;
RA   Leung J.K., Tam T., Wang J., Sadar M.D.;
RT   "Isolation and characterization of castration-resistant prostate
RT   cancer LNCaP95 clones.";
RL   Hum. Cell 34:211-218(2021).
//